Share ownership Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 09:58:44 17/04/2026 BST			5-day change	1st Jan Change
1,800.75 ^DKK	+0.60%		+0.36%	-11.37%

04-15	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
04-14	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	66,187,186	63,498,948 ( 95.94 %)	2,647,007 ( 3.999 %)	95.94 %

Major shareholders: Genmab A/S

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 4.351 %	2,795,626	4.351 %	738 M kr
GENMAB A/S 4.306 %	2,766,533	4.306 %	731 M kr
Jan van de Winkel 1.026 %	658,932	1.026 %	174 M kr
AllianceBernstein Investments Taiwan Ltd. 0.702 %	451,050	0.702 %	119 M kr
Nykredit Bank A/S (Investment Management) 0.5177 %	332,609	0.5177 %	88 M kr
Robert W. Baird & Co., Inc. (Equity) 0.3408 %	218,967	0.3408 %	58 M kr
Sjunde AP-fonden 0.1611 %	103,520	0.1611 %	27 M kr
State Street Global Advisors Ltd. 0.144 %	92,547	0.144 %	24 M kr
Carmignac UK Ltd. 0.109 %	70,041	0.109 %	19 M kr
Svenska Handelsbanken AB (Denmark) 0.0932 %	59,870	0.0932 %	16 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 2.244 %	14,418,462	2.244 %	387 M kr
AllianceBernstein LP 1.693 %	10,877,094	1.693 %	292 M kr
Paradigm BioCapital Advisors LP 1.096 %	7,039,834	1.096 %	189 M kr
Arrowstreet Capital LP 0.7748 %	4,978,058	0.7748 %	134 M kr
Aperio Group LLC 0.6811 %	4,376,179	0.6811 %	117 M kr
Renaissance Technologies LLC 0.5436 %	3,492,850	0.5436 %	94 M kr
Harding Loevner LP 0.5245 %	3,370,143	0.5245 %	90 M kr
Eaton Vance Management 0.2855 %	1,834,439	0.2855 %	49 M kr
First Trust Advisors LP 0.2078 %	1,335,273	0.2078 %	36 M kr
Goldman Sachs Asset Management LP 0.2075 %	1,333,303	0.2075 %	36 M kr
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	115.56%
Other	5.41%
Genmab A/S	4.31%
Individuals	1.09%
ABC arbitrage SA	0.16%
SEI Investments Co.	0.12%
Fifth Third Bancorp	0.08%
Regions Financial Corp.	0.02%
Banco Bilbao Vizcaya Argentaria SA	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	86.43%
Bermuda	26.78%
Denmark	5.01%
United Kingdom	2.88%
Individuals	1.09%
Canada	0.81%
Taiwan	0.7%
Norway	0.43%
Switzerland	0.32%
Germany	0.3%
Ireland	0.29%
France	0.29%
Sweden	0.27%
Netherlands	0.2%
Australia	0.17%
Italy	0.13%
Finland	0.12%
Singapore	0.09%
Belgium	0.09%
Luxembourg	0.07%
Cayman Islands	0.06%
Japan	0.05%
Spain	0.04%
Austria	0.04%
Portugal	0.02%
China	0.02%
New Zealand	0.01%
Israel	0.01%
Hong Kong	0.01%
South Africa	0.01%
Mexico	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

2,973

Sector

Biotechnology & Medical Research

Calendar

05-07 - Earnings release - Q1 2026

More about the company